158 related articles for article (PubMed ID: 30405638)
1. LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens.
Brunetti G; Rizzi R; Storlino G; Bortolotti S; Colaianni G; Sanesi L; Lippo L; Faienza MF; Mestice A; Curci P; Specchia G; Grano M; Colucci S
Front Immunol; 2018; 9():2459. PubMed ID: 30405638
[TBL] [Abstract][Full Text] [Related]
2. LIGHT/TNFSF14 regulates estrogen deficiency-induced bone loss.
Brunetti G; Storlino G; Oranger A; Colaianni G; Faienza MF; Ingravallo G; Di Comite M; Reseland JE; Celi M; Tarantino U; Passeri G; Ware CF; Grano M; Colucci S
J Pathol; 2020 Apr; 250(4):440-451. PubMed ID: 31990039
[TBL] [Abstract][Full Text] [Related]
3. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
Edwards JR; Sun SG; Locklin R; Shipman CM; Adamopoulos IE; Athanasou NA; Sabokbar A
Arthritis Rheum; 2006 May; 54(5):1451-62. PubMed ID: 16649193
[TBL] [Abstract][Full Text] [Related]
4.
Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
[TBL] [Abstract][Full Text] [Related]
5. LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease.
Brunetti G; Rizzi R; Oranger A; Gigante I; Mori G; Taurino G; Mongelli T; Colaianni G; Di Benedetto A; Tamma R; Ingravallo G; Napoli A; Faienza MF; Mestice A; Curci P; Specchia G; Colucci S; Grano M
Oncotarget; 2014 Dec; 5(24):12950-67. PubMed ID: 25460501
[TBL] [Abstract][Full Text] [Related]
6. Investigation of osteoclastogenic signalling of the RANKL substitute LIGHT.
Hemingway F; Kashima TG; Knowles HJ; Athanasou NA
Exp Mol Pathol; 2013 Apr; 94(2):380-5. PubMed ID: 23391709
[TBL] [Abstract][Full Text] [Related]
7. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
8. Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.
Sabokbar A; Mahoney DJ; Hemingway F; Athanasou NA
Clin Rev Allergy Immunol; 2016 Aug; 51(1):16-26. PubMed ID: 26578261
[TBL] [Abstract][Full Text] [Related]
9. Inflammation induces osteoclast differentiation from peripheral mononuclear cells in chronic kidney disease patients: crosstalk between the immune and bone systems.
Cafiero C; Gigante M; Brunetti G; Simone S; Chaoul N; Oranger A; Ranieri E; Colucci S; Pertosa GB; Grano M; Gesualdo L
Nephrol Dial Transplant; 2018 Jan; 33(1):65-75. PubMed ID: 28992140
[TBL] [Abstract][Full Text] [Related]
10. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
11. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
12. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts.
Kindle L; Rothe L; Kriss M; Osdoby P; Collin-Osdoby P
J Bone Miner Res; 2006 Feb; 21(2):193-206. PubMed ID: 16418775
[TBL] [Abstract][Full Text] [Related]
13. CD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study.
Petitprez V; Royer B; Desoutter J; Guiheneuf E; Rigolle A; Marolleau JP; Kamel S; Guillaume N
Int J Lab Hematol; 2015 Feb; 37(1):29-35. PubMed ID: 24661393
[TBL] [Abstract][Full Text] [Related]
14. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis.
Colucci S; Brunetti G; Cantatore FP; Oranger A; Mori G; Quarta L; Cirulli N; Mancini L; Corrado A; Grassi FR; Grano M
J Pathol; 2007 May; 212(1):47-55. PubMed ID: 17370327
[TBL] [Abstract][Full Text] [Related]
15. Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo.
Ai LS; Sun CY; Wang YD; Zhang L; Chu ZB; Qin Y; Gao F; Yan H; Guo T; Chen L; Yang D; Hu Y
Int J Cancer; 2013 Sep; 133(5):1074-84. PubMed ID: 23420490
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Enhanced Osteoclastogenesis in Alkaptonuria.
Brunetti G; Tummolo A; D'Amato G; Gaeta A; Ortolani F; Piacente L; Giordano P; Colucci S; Grano M; Papadia F; Faienza MF
Am J Pathol; 2018 Apr; 188(4):1059-1068. PubMed ID: 29353057
[TBL] [Abstract][Full Text] [Related]
17. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
18. Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL).
Nicholson GC; Malakellis M; Collier FM; Cameron PU; Holloway WR; Gough TJ; Gregorio-King C; Kirkland MA; Myers DE
Clin Sci (Lond); 2000 Aug; 99(2):133-40. PubMed ID: 10918046
[TBL] [Abstract][Full Text] [Related]
19. Sera of patients with axial spondyloarthritis (axSpA) enhance osteoclastogenic potential of monocytes isolated from healthy individuals.
Korkosz M; Czepiel M; Guła Z; Stec M; Węglarczyk K; Rutkowska-Zapała M; Gruca A; Lenart M; Baran J; Gąsowski J; Błyszczuk P; Siedlar M
BMC Musculoskelet Disord; 2018 Dec; 19(1):434. PubMed ID: 30522483
[TBL] [Abstract][Full Text] [Related]
20. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
Giuliani N; Colla S; Rizzoli V
Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
